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Abstract
Background: Hepatitis C infection is a major public health concern in low- and middle-income countries where an
estimated 71.1 million individuals are living with chronic infection. The World Health Organization (WHO) has
recently released new guidance for hepatitis C virus (HCV) treatment programs, which include improving the access
to new direct-acting antiviral agents. In Vietnam, a highly populated middle-income country, the seroprevalence of
HCV infection is approximately 4% and multiple genotypes co-circulate in the general population. Here we review
what is currently known regarding the epidemiology of HCV in Vietnam and outline options for reducing the
significant burden of morbidity and mortality in our setting.
Methods: We performed a systematic review of the currently available literature to evaluate what has been
achieved to date with efforts to control HCV infection in Vietnam.
Results: This search retrieved few publications specific to Vietnam indicating a significant gap in baseline
epidemiological and public health data. Key knowledge gaps identified included an understanding of the
prevalence in specific high-risk groups, characterization of circulating HCV genotypes in the population and likely
response to treatment, and the extent to which HCV treatment is available, accessed and utilized.
Conclusions: We conclude that there is an urgent need to perform up to date assessments of HCV disease burden
in Vietnam, especially in high-risk groups, in whom incidence is high and cross infection with multiple genotypes is
likely to be frequent. Coordinating renewed surveillance measures with forthcoming HCV treatment studies should
initiate the traction required to achieve the WHO goal of eliminating HCV as a public health threat by 2030, at least
in this region.
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Background
Approximately 71.1 million people worldwide have chronic
hepatitis C virus infection, resulting in over 500,000 deaths
each year and creating a substantial burden on healthcare
services [1–4]. The prevalence of hepatitis C infection is
estimated to be 1%, although the highest burden (85%) of
chronic infection is in low and middle income countries
(LMICs) [1–4].
Hepatitis C virus (HCV), a single-stranded positive
RNA virus, can cause individual infection with multiple
subtypes, and therefore knowledge of viral genotype is
particularly important for predicting virological and
clinical treatment response. Genotype distribution varies
geographically and is known to be particularly diverse in
Southeast Asia [1].
Recently, the treatment options available for chronic
hepatitis C infection have undergone a revolution with
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development of the direct-acting antivirals (DAAs) [5].
Treatment regimes containing drugs from this new class
have demonstrated significantly higher rates of sustained
virological response (SVR) compared to standard inter-
feron- (IFN) and ribavirin-focused regimes [6, 7]. Add-
itional benefits of this class include shorter treatment
durations, oral administration and fewer side-effects. It
has been estimated that, with unrestricted access to these
costly DAA-containing regimes, more than 90% of HCV
infected patients could attain SVR and thus achieve a
definitive cure [8].
In May 2016, the World Health Organisation (WHO)
launched a new global strategy to eliminate viral hepa-
titis as public health threat by 2030 [9]. A key priority in
these recommendations is to ensure open access to the
DAAs [10]. However, individuals living in LMICs, are
unlikely to be able to afford regimes containing these
new costly treatments [10]. Ongoing efforts to ensure
equity of access include the development of generic drug
formulations [10, 11].
The Socialist Republic of Vietnam has a population ex-
ceeding 93 million people. Since the mid-1980s there
have been dramatic improvements in the key develop-
ment indicators of this Southeast Asian country, includ-
ing increases in life expectancy, gross-domestic product
and expanding state and private healthcare provision
[12]. This includes a new national strategy to improve
access to viral hepatitis diagnostic and treatment services
[12]. To achieve the WHO stated goal of HCV elimin-
ation as a public health problem, understanding how the
control of HCV in countries such as Vietnam could be im-
proved, is vital. This article aims to review the currently
available published literature regarding the epidemiology,
virological features and the current treatment options
available for hepatitis C infection in Vietnam. We use
these data to propose measures which could help in redu-
cing the burden of HCV infections in Vietnam.
Methods
Search strategy and selection criteria
We searched PubMed-, MEDLINE- and Embase®-indexed
articles for English-Vietnamese languages articles in June
2016, according to the PRISMA guidelines (Fig. 1) [13].
Databases were searched using a combination of the
following MeSH terms and keywords, including (Hepa-
titis C virus OR HCV) AND Vietnam AND (Prevalence
OR Epidemiology OR Surve* OR Seroprevalence) (OR
hepatitis C). No date restriction was used although in-
cluded articles/data were restricted to original research
articles relating to hepatitis C infection and HCV in
Vietnam only, and on those published in either English
or Vietnamese. We further searched the clinical trials
registry http:/ClinicalTrial.gov for treatment trials
Fig. 1 Flow chart of studies included in data synthesis. * Other sources from which records were obtained include Clinicaltrials.gov (n = 9, see
Table 2) and Standard Operating Procedures for the identification, diagnosis and management of Hepatitis C infection published in Vietnamese
and identified through web searches (n = 5)
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currently underway or completed in Vietnam using the
search term “Hepatitis C” AND “Vietnam”.
After performing the literature searches, one author
(AB) extracted and screened the titles and abstracts before
selecting and reviewing the full-text articles. The following
data were extracted from each article: first author’s name,
publication year, country of origin, date of study, type of
patient group, and additional details of epidemiology,
seroprevalence, HCV RNA positivity figures, treatment
availability etc.
Results
Search results
A total of 99 abstracts for manuscripts published be-
tween September 1990 and June 2016 were identified.
Of these, 42 contained information relevant for our re-
view and full texts were retrieved [11, 14–60] (Table 1
and Fig. 1). The majority of publications (73.8%, 31/42)
assessed the prevalence of HCV infection specifically in
high-risk groups, including HIV infected patients, inject-
ing drug users (IDU), community sex workers (CSW),
men that have sex with men (MSM) and renal haemodi-
alysis patients [11, 17, 21–23, 25, 26, 28, 29, 31, 32, 34,
36, 37, 39, 41–47, 51–53, 55–60] (Table 1). Online
search for Vietnamese articles retrieved one research
publication and four Standard Operating Procedures
(SOPs); only the Vietnamese research paper retrieved
from a Vietnamese journal was included in this
analysis [38].
Twenty one percent (9/42) of the publications
reported data from Ho Chi Minh City (HCMC) or from
the southern Vietnam region (Table 1), while 52.3% (22/
42) reported studies conducted in the north of the
country, principally in Hanoi and surrounding provinces
[18, 22, 27, 32, 36, 47, 49, 52, 53] (Table 1). Eight of forty
two retrieved publications characterized the diversity of
HCV genotypes in Vietnam [14, 16, 21, 33, 34, 48, 50,
51] (Table 1). Two manuscripts were reviews assessing
risk factors associated with HCV acquisition in Vietnam
[11, 24]. One article, retrieved from a Vietnamese web-
site assessed the prevalence of HCV in the Vietnamese
ethnic minority [38].
Nine clinical trials were found registered with Clinical-
Trials.com (see Table 2). Five out of nine were com-
pleted but no results have been published to-date, two
are completed with results available, one is active but no
recruiting, while one is actively recruiting (Fig. 1). Only
the two clinical trials that had published results were
included in the review, the remaining seven studies have
been excluded.
The epidemiology of hepatitis C in Vietnam
In Vietnam, the background prevalence of HCV infec-
tion in the general population, at least historically,
appears to vary depending on the region studied. In
1994 it was estimated that the seroprevalence in individ-
uals without liver disease was 9% (43/491; 95% CI,
6.4%–11.5%) and 4% (18/511; 95% CI, 2.3%–5.6%) in
HCMC and Hanoi, respectively [53] (Fig. 2). By 1998 it
was estimated that in HCMC, the HCV seroprevalence
in patients with underlying liver disease was 23% (69/
289; 95% CI, 18.1%–27.8%) and in this population, HCV
RNA was detectable in blood of 61% (42/69; 95% CI,
49.4%–72.5%) of the individuals [47]. This same study
reported an HCV seroprevalence in healthy individuals
in Da Lat (in the Southern Highlands) of 1% (9/890; 95%
CI, 0.9%–1.0%); HCV RNA was detected in 44% (4/9) of
these individuals [47]. Four years later in 2002, HCV
RNA detection in HCMC was estimated to be 2% (2/
100; 95% CI, 1.3%–5.3%) in apparently healthy individ-
uals and 33% (45/234; 95% CI, 27.0%–39.0%) in patients
with liver disease [15]. In Binh Thuan province (212 km
northeast of HCMC) HCV seroprevalence in the general
population between 2005 and 2007 was estimated to be
3.3% (17/509; 95% CI, 1.7%–4.8%); the male population
exhibited a higher burden of seropositive samples (3.3%)
than women (1.8%), and HCV RNA was detected in
52.9% (9/17) of the identified anti-HCV positive individ-
uals (Fig. 2) [30]. Furthermore, one article was retrieved
from a Vietnamese journal. The original manuscript was
in Vietnamese and only the abstract was translated in
English. The manuscript assessed the seroprevalence of
HCV in the Vietnamese ethnic minority in the north of
Vietnam and the detected seroprevalence in 1305 indi-
viduals was 1.22% (95% CI, 0.6%–1.7%) in 2011 [38].
The majority of the remaining publications evaluated
HCV prevalence in specific high-risk groups (Table 1).
These data estimated that 89% (1255/1434; 95% CI,
87.3%–90.6%) of IDU in Nguyen province (Northern
Vietnam) were HCV RNA positive between 2005 and
2007 and 35% (502/1434; 95% CI, 32.5%-37.4) were
HIV/HCV co-infected [29]. Similar figures were reported
in Hai Phong province (northern Vietnam) in 2014 (Fig.
2), where the prevalence of HCV in HIV-infected
individual was 89.4% (93/104; 95% CI, 82.1%–96.6%).
This study also reported that the majority of HCV cases
presented with clinical features of advanced liver fibrosis
and cirrhosis [26].
Between 2005 and 2012, several studies were con-
ducted around Vietnam (including HCMC, Hanoi,
Hai Phong Province, Da Nang, Khanh Hoa Province
and Can Tho), which aimed to determine HCV sero-
prevalence in patients undergoing renal haemodialysis
or receiving multiple blood transfusions [23, 37].
These six hospital-based studies found an apparent
iatrogenic HCV seroprevalence of 26% (n = 153/575;
95% CI, 22.4%–29.5%) and was similar at all sites
assessed.
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In 2010, a study estimated the prevalence of HCV
infection in MSM in the south of Vietnam (Can Tho
and HCMC) and in the north of Vietnam (Hai Phong
Province and Hanoi) [25]. The overall seroprevalence of
infection in 1588 male participants was 28.4% (95% CI,
26.1%–30.6%) [25]; 29% of the individuals were co-
infected with HIV and more northerly regions observed
a higher HCV and HCV/HIV co-infection prevalence
[25]. A single publication from 1997 assessed the
frequency of HCV infection in patients with chronic
hepatitis in HCMC, and concluded that HCV was the
underlying etiology in 19–27% of chronic hepatitis cases
[19]. However, no indication of the sample size used to
derive this estimate was provided.
The molecular epidemiology of HCV in Vietnam
A study conducted in four major conurbations in
Vietnam – Hanoi, Hai Phong Province, Da Nang, Khanh
Hoa Province and Can Tho, identified HCV genotypes 1,
6, 3 and 2 in 59.9% (n = 169), 37.9% (n = 107), 1.8%
(n = 5) and 0.4% (n = 1) of samples collected from
mixed healthy and high-risk populations, respectively
Table 1 Characteristics population-based studies reporting prevalence of HCV in Vietnam
Year First Author Prevalence Group Type Sample Size Reference
1998 Kakumu 1% General Population 1179 [47]
2007 Nguyen 1% General Population 837 [45]
2015 Quesada 4.7% General Population 27/571 [27]
2015 Do 3.3%
1.3%*
General population 509 [30]
2003 Tran 2% General population 334 [15]
1996 Corwin 2% General population 188 [49]
2012 Sereno 0.38–4.3% General population NAb [21]
2016 Martinello 42.5% HIV 89.452a [24]
2015 Nadol 53.3% HIV/IDU 3010 [32]
2015 Zang 88% HIV 1434 [29]
1999 Follézou >80% HIV 280 [18]
2012 Durier 22.9% HIV 110 [20]
2016 Nguyen 89% HIV 104 [26]
2016 Hser 74% HIV/IDU NAb, c [11]
2012 Sereno 95.8% HIV/IDU NAb [21]
2012 Gish 87% IDU NAb [36]
1998 Kakumu 47% Liver Disease 1179 [47]
2003 Tran 10% Liver disease 334 [15]
1996 Corwin 10% Liver Disease 188 [49]
2004 Buchy 9% Liver disease 45 [46]
2012 Gish 23% Liver disease NAb [36]
1993 Cordier 2% Hepatocarcinoma 152 [54]
2010 Bjoerkvoll 12.7% Blood donors 1305 [38]
2012 Viet 76.4% Blood Donors 1200a [40]
1994 Song 20.6% Blood Donors 491 [52]
2012 Dunford 26.6% Dialysis 8652a [37]
2016 Duong 8% Dialysis 142 [22]
2015 Duong 6% Dialysis 113 [31]
2012 Gish 54% Hemodialysis NAb [36]
2016 Nadol 28.4% MSM 1588 [25]
2012 Dunford 8.7% CSW 8652a [37]
*Presence of HCV RNA
aMulti countries study
bNA Not applicable
cEstimate
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[37]. While genotype 1 was the most prevalent HCV
genotype in all four areas, the genotype distribution
ranged from 47% in Khanh Hoa Province to 81% in Da
Nang [37]. These four genotypes (1–3, 6, and) were
identified in dialysis and multi-transfused individuals
with nine recognized subtypes (1a, 1b, 2a, 3a, 3b, 6a, 6e,
6 h, 6 l) [39]. A further study similarly identified HCV
genotype 1 as the predominant virus circulating in MSM
in Hanoi, Hai Phong Province, HCMC and Can Tho
[25]. Additionally, plasma samples from 97 HCV in-
fected individuals were molecularly characterized be-
tween 2003 and 2010 in HCMC. The RNA sequences
obtained from these samples suggested that genotypes 1b
and 2a were imported from East Asia, 1a from the United
States, 2i, 2j and 2 m imported from France [33, 58]. They
also identified an additional 4 subtypes of genotype 6 (6a,
6ax, 6xb and 6xc) with no obvious international link [34].
Clinical trials
Of the nine trials registered on ClinicalTrials.gov, only
two had published results available at time of review
[61, 62]. Both studies were sponsored by Debiopharm
International SA and neither the source country infor-
mation nor the locations where trial participant recruit-
ment was performed within the country have been
specified. Both studies were multicenter international tri-
als to assess the treatment responses (SVR to single agent
or combination treatment) to the synthetic cyclosporine-
like agent, Alisporivir, a novel host-targeting antiviral
(HTA) agent [61, 62].
Discussion
Our literature search identified a paucity of published
data regarding the nature or burden of HCV infection
in Vietnam. Studies in the publications identified were
generally conducted in high-risk populations and
focused in the more populous northern provinces
(around Hanoi) and southern provinces (around
HCMC) of the country. In addition, most studies have
measured HCV antibody seroprevalence rather than
HCV RNA prevalence, which would more reliably indi-
cate the numbers of individuals with active infection.
As elsewhere, the available literature suggested that
blood transfusions, intravenous drug use, and unsafe
therapeutic injections were a likely common source of
HCV infection in the Vietnamese populations studied.
Furthermore, the data suggests while the HCV sero-
prevalence in the general population is approximately
4% (18/511; 95% CI, 2.3%–5.6%) in Hanoi and 9% (43/
491; 95% CI, 6.4%–11.5%) in Ho Chi Minh City, which
is high in comparison to America or Europe [63, 64],
this is likely to be even higher in IDU (55.6%, n = 556/
1000; 95% CI, 52.8%–58.3%), MSM (38.8%; n = 1558; 95%
CI, 36.3%–41.2%), and hemodialysis patients (26.6%,
n = 153/575; 95% CI, 22.4%–29.5%) [23, 31, 53, 57] . There
are still substantial gaps in our understanding of the
molecular epidemiology of HCV infection in Vietnam,
however the limited findings from the few studies
that have been conducted suggest that multiple (≥4)
HCV genotypes and subtypes are circulating in the
population [25, 37].
Table 2 List of the clinical trials conducted in Vietnam to date a
Year Title City Sponsor Status
2010–2016 Hepatic Safety of Raltegravir Versus Efavirenz as HIV Therapy for
Patients With HIV and HCV Coinfection
Ho Chi Minh
City, Hai Phong
University of Hawaii Active, not
recruiting
2014–2016 The Study of Safety, Pharmacokinetics, Pharmacodynamics of
Peglamda (Peginterferon Lamda 1) on Healthy Volunteers and
the Preliminary Evaluation of Peglamda and Hepasig (Ribavirin)
Treatment’s Effects on Chronic Hepatitis C Patients
Unknown Nanogen Pharmaceutical
Biotechnology Co., Ltd
Completed
2015–2016 Feasibility of Interventions on People Who Inject Drugs in Vietnam
Implementation of a Sexual Health Intervention for Young Men
Who Have Sex With Men (MSM) in Two Vietnamese Cities
Ho Chi Minh
City, Hanoi
Inserm-ANRS Completed
2013–2016 HCV Treatment in HIV Co-Infected Patients in Asia Hanoi amfAR, Completed
2016 Long Term Follow-up Study to Assess Durability of Sustained
Virologic Response in Alisporivir-treated Hepatitis C Patients
Unknown Debiopharm International SA Completed,
has results
2011–2016 Efficacy and Safety of Alisporivir Triple Therapy in Chronic
Hepatitis C Genotype 1 Treatment-naïve Participants
Unknown Debiopharm International SA Completed,
has results
2016–2017 Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose
Combination for 12 Weeks in Participants With Chronic HCV
Unknown Gilead Sciences Recruiting
2015 3-year Follow-up Study to Assess the Viral Activity in Hepatitis C
Patients Who Failed Feeder DEB025/Alisporivir Study
Novartis Pharmaceuticals Completed
2014–2016 Implementation of a Sexual Health Intervention for Young Men
Who Have Sex With Men (MSM) in Two Vietnamese Cities
Hanoi National Development and
Research Institutes, Inc.
Completed
aFor further details please see the following website: ClinicalTrials.gov
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Ascertaining the burden of hepatitis C in Vietnam
Ascertaining the true likely burden of infection in
Vietnam would facilitate advocacy for the implementation
of disease specific strategies and guidelines, and provide
useful baseline data for further epidemiological measure-
ments. Our search identified that HCV seroprevalence in
the population may be high (1–4%) compared to other
countries in the region [3, 27, 53]. For example, several
large-scale seroprevalence studies have reported HCV
estimates of asymptomatic Chinese ranging from 0.39
to 3.2% depending of the region [65]. Other Asian
countries such as Japan, India or Indonesia reported an
HCV seroprevalence of between 2.3, 0.9 and 2.1%
respectively [4].
2003-2007
2008-2009
2014
1994
2009-2010
2002
2012
Fig. 2 Vietnam Map and summary of the main studies conducted so farA summary of the main studies performed in Vietnam to-date measuring
the prevalence of HCV viral detection (PCR positivity) in selected populations by year of study publication and geographic location. * Data for
‘General adult healthy populations’ is for measured anti-HCV antibody seroprevalence. The map represents the location where the main studies
have been conducted and summarized the HCV prevalence or seroprevalence observed during the studies in different groups, such as IDU, MSM,
liver disease, hemodialysis and multi-blood transfusion and general population
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Observations supporting the speculation that the true
seroprevalence might be underestimated include data
from neighboring countries such as China, where the
reported rate of HCV infections increased more than
10-fold (from 21,000 reported cases/year to 210,000 re-
ported cases/year) between 2003 and 2011 [66]. Reasons
for this increase may include an increase in life expect-
ancy and/or the increased detection/occurrence of new
infections due to better surveillance and improved
diagnostics. The ageing of the population creates two
potentially major pressures on health care finances:
increased utilization of health services and decreased
revenues (as a declining share of the population is
economically active).
Further insights into the current HCV situation in
Vietnam may be provided by two non-resident popula-
tions; data on HCV infection in USA veterans after the
Vietnam/American war suggest that returning veterans
had a higher risk (10–17%) of being HCV infected than
the general North American population (1.3%) [63, 64, 67].
This conflict was associated with the highest rate of HCV
acquisition in comparison to any that the US has been en-
gaged in. More recently, it was observed that Vietnamese
migrants to other countries have a higher prevalence
(5.8%) of HCV infection when compared to the autoch-
thonous population (1.3%) [60, 68].
The transmission of HCV infection in clinical settings
is still particularly concerning in Vietnamese healthcare
facilities; the high HCV prevalence (26%) in haemodialy-
sis patients [23, 31, 57] has not been observed in other
Asian-Pacific countries (0.7–18.1%) [69]. This literature
review also found a high seroprevalence (27%) in other
high-risk populations including IDU, MSM, and CSW,
similar data has been reported from studies conducted
between the Myanmar and Chinese border region [70].
We therefore speculate that the seroprevalence in the
general population might be higher than that currently
estimated as the limited data currently available (only 42
publications published in over two decades) is from
studies performed in only a few locations across Vietnam
and which mostly had relatively small sample sizes upon
which to base these calculations. Of note, the two most
recent and larger studies performed to estimate sero-
prevalence in the general population have found an
HCV prevalence of 3.3 and 4.7%, respectively [27, 30].
Identifying the genetic characteristics of HCV to improve
public health
In addition to assessing the burden of HCV disease,
further data is required regarding HCV genotype, viral
mutations and viral loads in HCV infected patients in
order to assess how to implement the recent HCV treat-
ment guidance, and to estimate the cost-benefit of an
integrated HCV control program.
While currently available data are limited, they imply a
broad genetic diversity within circulating HCV strains in
all parts of the country [33, 34, 37, 39, 58]. More de-
tailed phylogenetic approaches have proposed that the
HCV population has been influenced by the inter-
national turmoil of the past, with importation of geno-
types that are more typically associated with North
America, Europe and other parts of Asia [34]. This gen-
etic variation can also be observed in high-risk groups,
meaning that the formation of a local treatment policy
may be more complex than in other locations. For ex-
ample, the distribution of HCV genotype in haemodialy-
sis patients is variable according to the geographical
region, this may be due to a lack of infection control and
or point source outbreaks [37]. This genotype distribution
is in contrast to other countries in Asia, such as China,
where hemodialysis patients are predominantly affected
by genotype 2 HCV [71, 72]. An improved understanding
of the genotype distribution and frequency of viral treat-
ment mutations among Vietnamese patients will facilitate
the development of appropriate local guidelines.
Current treatment options, molecular challenges and
social taboos
Early diagnosis and access to treatment are essential
components for an effective HCV control program in
Vietnam. As in most LMICs, current treatment for HCV
infection in Vietnam is limited to interferon-based (IFN-
gamma and pegylated-IFN) therapy [10]. More recently,
some patients have been treated with newer DAA agents
at the Hospital for Tropical Diseases (HTD) in HCMC,
where more than 18,000 patients with viral hepatitis are
assessed each year. Further clinical treatment studies
have received funding and are planned to commence in
the near future [73].
The more widespread introduction of the DAAs is hin-
dered by a lack of data regarding HCV genotype distribu-
tion and viral treatment mutations [74]. This lack of data
is especially problematic for the early detection of treat-
ment resistance mutations, which occurred previously
with hepatitis B treatment and HCV treatment in Japan
and North America [75–77]. Furthermore, the efficacy of
DAAs against some of the less common genotypes, such
as genotype 6 which was frequently identified in previ-
ously studies, is not well established [78].
Other barriers to increasing the utilization of HCV
treatment in resource-limited settings such as Vietnam
include high costs, a perceived complexity in treatment
regimes and bureaucratic support for importation, li-
censing and distribution of medicines for which specific
clinical trial data in the local populations is lacking.
Vietnam is a rapidly developing country, whose GDP
per-capita has increased from $1095 to $1684 from 2004
until 2014 [79]. However, the per capita income remains
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low (~ $1024) [80] with limited annual spending on
healthcare (according to WHO, approximately $264 in
2006) [80]. A large proportion of people in Vietnam do
not invest in health insurance and even those who do
may not have full coverage to expensive treatment
courses: pegylated-interferon courses are reimbursed at
30% ($10,000–18,000 for a 48 week treatmentcourse),
and this partial reimbursement is based on doctor opin-
ion only, with no allowance given for those in high-risk
populations such as haemodialysis patients [81, 82].
While the treatment of HCV infection requires pre-
scription from a medical practitioner, a further concern
is the non-completion of treatment courses due to high
costs and changes in family/patient financial circum-
stances. Some patients may also travel to other countries
in the region where medications, which may be sub-
standard, might be more affordable. Incomplete or inad-
equate treatment courses are likely to lead to increased
rates of viral resistance, which has been previously
widely observed in hepatitis B treatment programs in
Vietnam [83, 84]. Further, PEG + INF + RBV remains
(as 2016) the first line of therapy for chronic patients in
many part of Asia, Vietnam included [85].
Study limitations
The majority of the studies included here had small
sample sizes and concentrated on groups of individ-
uals at known high-risk of acquiring HCV infection
thus risking an overestimation bias. Given the hetero-
geneity of the study populations sampled, in addition
to the broad time period and diverse geographic loca-
tions described, more accurate meta-analysis is not
currently feasible. Thus, a considerable knowledge gap
remains regarding the likely true burden of chronic
HCV infection in the general, healthy adult Vietnam-
ese population.
Conclusions
Relatively little is known regarding the burden of HCV
infection in the general population in Vietnam. Available
data suggest that the seroprevalence could be higher
than previously assumed, especially in known high-risk
groups such as patients undergoing haemodialysis. Lim-
ited data predict a broad distribution of HCV genotypes
and, to-date, very few HCV treatment trials have been
performed in Vietnam. While HCV control programs in
Vietnam are in their infancy, there is an urgent need for
more detailed disease burden and viral genotyping data,
which, in addition to planned treatment studies, could
be used to inform the development of local HCV treat-
ment strategies and thus eventual attainment of the
2030 elimination target.
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